Montag & Associates’s AnaptysBio ANAB Stock Holding History

Montag & Associates’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$276	–	960
2025 Q3	$276	Buy	+9	New	+$207	﹤0.01%	1109

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Montag & Associates's ANAB Position: Q4 2025 in Review

Montag & Associates sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 9 shares — an estimated $276 sold.

Montag & Associates first reported a position in ANAB in Q3 2025 and held it in 1 quarter. The position peaked at $276 in Q3 2025. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

Montag & Associates reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
Montag & Associates sold 9 AnaptysBio shares in Q4 2025, an estimated $276.
Montag & Associates first reported a position in AnaptysBio in Q3 2025 and held it in 1 quarter.
Montag & Associates's AnaptysBio position peaked at $276 in Q3 2025.
179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.